Showing results (1341-1350 of 1,437) with videos related to

Sort By:
Pageof 144
Cancer Cell|December 7, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMaria E Figueroa, Omar Abdel-Wahab, Chao Lu, et al.
Gastroenterology|December 20, 2015
Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis BJang-June Park, David K Wong, Abdus S Wahed, et al.
Cancer Discovery|May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLCihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.
Science (New York, N.Y.)|August 11, 2012
Loss of the tumor suppressor BAP1 causes myeloid transformationAnwesha Dey, Dhaya Seshasayee, Rajkumar Noubade, et al.
Cancer Immunology Research|November 8, 2017
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast CancerJulia Tchou, Yangbing Zhao, Bruce L Levine, et al.
Cancer Discovery|April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaDavid T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Nature Biomedical Engineering|October 21, 2025
CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapyÁngel Ramírez-Fernández, Alexander J Dimitri, Fang Chen, et al.
Blood Advances|March 29, 2022
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemiaSaar Gill, Vanessa Vides, Noelle V Frey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2015
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor ResponsesMiriam E Mossoba, David C Halverson, Roger Kurlander, et al.
The Journal of Clinical Investigation|February 11, 2021
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
Pageof 144